Organisation paid for research Program year 2022 Source: CMS Open Payments

Central Coast Nephrology

Neither a doctor nor a teaching hospital

Research payments

$497,359

274 payments

Through program year 2022, Central Coast Nephrology is reported as receiving $497,359 in research payments, across 274 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$335	1
2021	Research	$44,674	4
2020	Research	$205,434	24
2019	Research	$246,916	245

Breakdown

Who paid Research payments · program years 2019–2022

Akebia Therapeutics Inc $400,826 265 payments
GlaxoSmithKline, LLC. $96,198 8 payments
Novartis Pharmaceuticals Corporation $335 1 payment

Studies the money was for Research payments · program years 2019–2022

Akb-6548-Ci-0014 $191,095 238 payments
A 28-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Grou $96,198 8 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $90,240 9 payments
Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $71,926 10 payments
Akb-6548-Ci-0014 $29,256 2 payments
Akb-6548-Ci-0015 $11,715 5 payments
Akb-6548-Ci-0015 $6,594 1 payment
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of Lnp023 in Primary Iga Nephropathy Patients $335 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.